Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. Nicox is headquartered in
Sophia Antipolis
(wisdom), gr, (Ἀντίπολις, antipolis) ("opposite city" from its position on the opposite side of the Var estuary from Nice, also former name of Antibes, part of the technology park)
, postal_code = 06220 (Vallauris), 06250 (Mo ...
, France, and its Chairman and CEO is Michele Garufi.
Nicox is listed on Euronext Paris (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration (FDA) approved products.
Pipeline
Nicox's lead program in clinical development is NCX 470, a novel, second-generation
nitric oxide
Nitric oxide (nitrogen oxide or nitrogen monoxide) is a colorless gas with the formula . It is one of the principal oxides of nitrogen. Nitric oxide is a free radical: it has an unpaired electron, which is sometimes denoted by a dot in its che ...
-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma. NCX 470 is designed to release both
bimatoprost
Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used ...
, which is marketed under the brand name LUMIGAN, and nitric oxide following instillation into the eye. Bimatoprost is a prostaglandin analog, the most widely used class of drugs for IOP lowering in patients with open angle glaucoma and ocular hypertension.
The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA(R) in glaucoma and ZERVIATE(TM), or cetirizine ophthalmic solution, in allergic conjunctivitis. It has ongoing partnerships with
Bausch & Lomb
Bausch + Lomb is an eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The compan ...
, Eyevance Pharmaceuticals and Ocumension Therapeutics.
Agreement with Ocumension
In 2019 Nicox and Ocumension Therapeutics signed an agreement to allow Ocumension the rights to develop and commercialize Zerviate, a certirizine ophthalmic solution, for the Chinese and South East Asian markets. The deal would see Nicox eligibile for up to $17.2 million, along with tiered royalties of between 5 and 9% of the net sales. In July 2021 the deal was amended and Ocumension paid $2 million to Nicox as an advance payment of the future development and regulatory milestones.
References
{{reflist
External links
Official website of NicOxNitric Oxide Knowledge Center - Website of NicOx
Pharmaceutical companies of France
Companies based in Provence-Alpes-Côte d'Azur
Companies listed on Euronext Paris